Eleva’s Factor H (CPV-104) program to enter clinic in 2025 in C3G, with dry AMD identified as potential second indication

Eleva的Factor H（CPV-104）项目将于2025年进入C3G临床试验，干性AMD被确定为潜在的第二个适应症。

FREIBURG IM BREISGAU, Germany, February 20, 2025 / Biotech Newswire / --

德国弗赖堡，2025年2月20日 /生物技术新闻社/ --

Eleva

提升

, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough moss-based platform, announced today the appointment of Dr. Martin Bauer, MD, as new Chief Medical Officer. His appointment reflects the growing maturity of Eleva’s proprietary pipeline, which includes Eleva’s Factor H (CPV-104) program, a novel complement regulator with therapeutic potential in several indications, and aGal (RPV-001), a best-in-class approach to treat Fabry disease..

，一家基于突破性的苔藓平台解锁难以生产的生物制剂的先锋企业，今天宣布任命马丁·鲍尔博士（Dr. Martin Bauer）为新的首席医学官。他的任命反映了Eleva公司专有研发管线的日益成熟，该管线包括Eleva的Factor H（CPV-104）项目——一种在多种适应症中具有治疗潜力的新型补体调节剂，以及aGal（RPV-001）——一种治疗法布里病的同类最佳方法。

Martin Bauer joins Eleva with over two decades of clinical development expertise, having held various management positions of increasing responsibility. His roles include senior and leadership positions at Atriva Therapeutics, Merck, Basilea, Otsuka, ICON, and Boehringer Ingelheim. He is board-certified in Anesthesiology, Rescue Medicine, and Medical Informatics, and has over 10 years of experience working in academic hospitals.

马丁·鲍尔拥有超过二十年的临床开发经验，曾担任过多个管理职位，职责不断增加。他曾在Atriva Therapeutics、默克、巴塞莱亚、大冢、ICON和勃林格殷格翰等公司担任高级和领导职务。他是麻醉学、急救医学和医学信息学的委员会认证专家，并在学术医院工作超过十年。

Martin Bauer earned his MD from Julius-Maximilians University of Würzburg, Germany..

马丁·鲍尔在德国维尔茨堡的尤利乌斯-马克西米利安大学获得了医学博士学位。

“With the clinical trial start for our second fully owned drug development program on the horizon, we have decided to appoint an experienced Chief Medical Officer orchestrating all of these activities,”

“随着我们第二个全资药物开发项目临床试验的启动在即，我们决定任命一位经验丰富的首席医学官来统筹所有这些工作。”

commented Björn Cochlovius Ph.D., Chief Executive Officer of Eleva.

Eleva首席执行官Björn Cochlovius博士评论道。

“Martin’s deep expertise in clinical development across several indications and modalities will be very valuable for Eleva’s continued growth as a drug development organization.”

“马丁在多个适应症和治疗模式的临床开发方面拥有深厚的专业知识，这对于 Eleva 作为一家药物开发组织的持续成长将非常有价值。”

Commenting on his appointment, Martin Bauer added:

马丁·鲍尔在评论他的任命时补充道：

“I’m thrilled to support Eleva as the company further strengthens its drug development activities with additional pipeline programs and potentially new indications being explored. Our Factor H program in particular has the potential to unlock a novel therapeutic mode-of-action that is clearly differentiated from the standard-of-care.”.

“我非常高兴支持Eleva，因为该公司通过增加管线项目和探索潜在的新适应症进一步加强了其药物开发活动。我们的Factor H项目尤其有潜力解锁一种新颖的治疗作用机制，这与标准疗法明显不同。”

For high resolution please click the image.

为了获得高分辨率，请点击图像。

+++ Meet the Eleva team during BIO-Europe Spring in Milan, Italy, March 17-19, 2025, to learn more about future collaboration and investment opportunities +++

+++ 2025年3月17日至19日，在意大利米兰举行的BIO-Europe Spring会议上，与Eleva团队会面，了解更多关于未来合作和投资机会 +++

ABOUT

关于

ELEVA

电梯

Eleva is a clinical-stage biopharmaceutical company unlocking difficult-to-produce biologics based on a breakthrough technology platform. The company’s proprietary drug development activities currently focus on complement disorders and enzyme replacement therapies. Factor H (CPV-104), a recombinant version of human complement Factor H, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025.

Eleva是一家临床阶段的生物制药公司，基于突破性技术平台解锁难以生产的生物制品。该公司专有的药物开发活动目前集中在补体疾病和酶替代疗法。重组人补体Factor H——Factor H（CPV-104）预计将于2025年上半年进入C3肾小球病（C3G）的临床研究。

The company’s aGal (RPV-001) program to treat Fabry disease has completed a Phase 1b clinical study with promising results. All programs are sourced from Eleva’s transformative moss-based expression system, which allows lab to GMP-scale manufacturing of challenging proteins with previously untapped therapeutic potential. .

该公司针对法布里病的aGal（RPV-001）项目已完成一项1b期临床研究，结果令人鼓舞。所有项目均源自Eleva革命性的苔藓基表达系统，该系统能够以实验室规模实现GMP级别生产，制造出具有前所未有的治疗潜力的复杂蛋白质。

Contacts

联系人

Eleva

提升

Fabienne Zeitter

法比安·泽特тер

Director Marketing

营销总监

This email address is being protected from spambots. You need JavaScript enabled to view it.

此电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

+49 761 470 99 0

+49 761 470 99 0

Valency Communications

价通信

Mario Brkulj

马里奥·布鲁克利

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到防垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

+49 160 9352 9951

+49 160 9352 9951

Keywords: Appointments and Schedules; Moss-based expression system; Biologics manufacturing; Biological Products; Complement Factor H; Macular Degeneration; Eleva; Martin Bauer; Factor H (CPV-104); C3 Glomerulopathy (C3G); Dry AMD; aGal (RPV-001); Fabry disease; Complement regulator; Drug development; Clinical development; Enzyme replacement therapy; GMP-scale manufacturing; BIO-Europe Spring; Björn Cochlovius.

关键词：预约和时间表；基于苔藓的表达系统；生物制品制造；生物产品；补体因子H；黄斑变性；Eleva；Martin Bauer；因子H（CPV-104）；C3肾小球病（C3G）；干性AMD；aGal（RPV-001）；法布里病；补体调节剂；药物开发；临床开发；酶替代疗法；GMP规模生产；BIO-Europe Spring；比约恩·科赫洛维乌斯。

Source: Biotech Newswire

来源：生物技术新闻专线